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Patients with distributive shock still have a high
mortality rate and remain an important issue for
intensivists. Management of catecholamine-resistant
shock in these patients poses a challenging problem.
Despite significant advances in the knowledge of its
pathophysiology, all innovative therapeutic approaches
and interventions have failed to improve outcome. In
the previous issue of Critical Care, Chawla and colleagues
explored the impact of angiotensin II administration in
patients with persistent hypotension despite adapted
hemodynamic resuscitation. The authors demonstrate
that, in case of distributive shock, angiotensin II is an
effective vasopressor therapy. Its impact on outcome
and adverse effects still needs to be further explored.trial. Nevertheless, one question should be debated: isIn a previous issue of Critical Care, Chawla and colleagues
tested, in a phase II randomized controlled trial, the
hemodynamic effects of angiotensin II, a natural vasopressor
hormone without any inotrope or chronotrope effects
[1]. In critically ill patients, distributive shock is
mainly represented by septic shock [2]. Its mortality rate,
after having decreased as the result of the implementation
of specific guidelines, still remains unacceptable at about
30% in most recent cohort studies [3]. Vasopressor-
refractory hypotension is the last stage before death.
Vascular hyporesponsiveness to catecholamines has
numerous origins, including nitric oxide overproduction,
upregulation of prostacyclin, excessive activation of
ATP-sensitive potassium channels and desensitization of
alpha adrenoreceptors [4]. Administration of very high* Correspondence: b.levy@chu-nancy.fr
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with many potential side effects such as tachyarrhythmia
or myocardial cell damage [5].
The present study of Chawla and colleagues was
designed to determine the appropriate dose of angiotensin
II in the setting of distributive shock with high cardiac
flow. The authors found an almost significant reduction in
norepinephrine dosing at a dose range of 1 to 40 ng/kg/
minute whereas a rebound of norepinephrine dosing was
systematically noticed upon angiotensin II cessation. No
clinically relevant adverse effect other than metabolic
alkalosis was experienced with angiotensin infusion.
This first clinical trial on the use of angiotensin II in
distributive shock raises many questions. Undoubtedly,
angiotensin II appears to be an effective vasopressor
even if statistical significance was never reached in this
there actually a need for a new vasopressor therapy?
This intentionally provocative issue reflects the limited
literature on the consequences of high catecholamine
dosing in refractory shock. First, the maximum tolerable
dose is still unknown [6]. Second, even though excessive
dosing is associated with tissue hypoperfusion, it is more
likely that, in a refractory shock state, adverse ischemic
effects are rather related to the shock itself. Finally, in a
recent retrospective study, high-dose norepinephrine,
particularly in the early phase of septic shock, was not
predictive of death [7]. In the present study, patients did
not receive high catecholamine dosing. Consequently,
patients for whom this new vasopressor therapy could
be beneficial were not identified.
Otherwise, no conclusion can be made regarding the
adverse effects with only 10 patients included in the
angiotensin II group. For the record, recent experimental
studies have demonstrated a downregulation of angiotensin
1 receptor-associated protein 1 in animals with septic shock
[8]. This downregulation could be an adaptive mechanism
to counteract the known pro-inflammatory effects of
angiotensin II [9]. In the past, numerous promisingCentral Ltd. The licensee has exclusive rights to distribute this article, in any
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unacceptable adverse effects. For example, the effects of a
nitric oxide synthase inhibitor in patients with septic shock
were assessed in a phase II, double bind, randomized study
[10]. In contrast to the trend toward better outcome in the
phase II study, phase III was associated with an increase in
overall mortality [11]. This increase in mortality mainly
reflected the adverse effects of the treatment on cardiac
function. More recently, high hopes have been invested in
vasopressin, a vasopressor without any cardiac effects, in
order to decrease catecholamine requirements and
improve outcome in septic shock patients. In a multicenter,
randomized, double-bind trial, adjunction of low-dose
vasopressin compared with norepinephrine alone was not
associated with any improvement in the 28- or 90-day
mortality rate [12]. Interestingly, considering the adverse
reactions to vasopressin, patients with a history or
coexistent acute coronary syndromes or severe heart
failure were excluded from this study. Nonetheless, more
patients in the vasopressin group had digital ischemia
[12]. Maybauer and colleagues [13] demonstrated that
selepressine, a selective vasopressin type 1a receptor
agonist, blocks vascular leak more effectively than the
mixed vasopressin type 1a receptor/vasopressin V2 receptor
agonist arginine vasopressin because of its lack of agonist
activity at the vasopressin V2 receptor.
In this work, and as judiciously stated by the authors,
the trial was only designed as a proof-of-concept and
dose-finding study. For now, it appears unreasonable to
judge the safety of this new vasopressor. Further studies,
with adapted sample size, are needed to determine the
adverse effects of such treatment. Consequently, even
though these finding are encouraging, we must be cautious
in the definition of the next clinical trials regarding this
drug so as not to repeat past failures.
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